Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side effects ...

(C cells are a kind of cell in the thyroid gland.) This side effect depended on Wegovy’s dosage and length of treatment. It’s not known if the same effect would happen in humans. Because of ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

Novo Nordisk said that patients taking a higher dose of its blockbuster obesity drug Wegovy lost more weight than those on a lower dose without experiencing an increase in side-effects ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

Novo Nordisk said that patients taking a higher dose of its blockbuster obesity drug Wegovy lost more weight than those on a lower dose without experiencing an increase in side-effects ...